The US Food and Drug Administration (FDA) has approved a subcutaneous injection version of Leqembi (lecanemab) for the treatment of early Alzheimer’s disease, marking a significant step forward in patient convenience. The new formulation, developed by Eisai and Biogen, can be administered at home rather than requiring hospital or clinic visits for intravenous infusion.
The approval, announced on 17 July 2026, covers a once-weekly injection that patients or caregivers can self-administer after proper training. This contrasts with the original intravenous formulation, which typically required bi-weekly infusions at a medical facility. The FDA’s decision is based on data showing comparable efficacy and safety profiles between the two administration routes.
For UK investors and pension holders, the news has direct implications for exposure to the pharmaceutical sector. Eisai’s shares rose 3.2% on the Tokyo Stock Exchange following the announcement, while Biogen’s stock gained 1.8% in pre-market trading in New York. The FTSE 100’s healthcare sector, which includes major pharma companies with Alzheimer’s pipelines, could see correlated moves as the treatment landscape evolves.
Analysts at Jefferies noted that the subcutaneous formulation addresses a key barrier to Leqembi’s uptake — the logistical burden of frequent hospital visits. “This approval could unlock a significantly larger patient population, particularly among older adults who may struggle with travel to infusion centres,” the analysts said in a note. However, they cautioned that pricing and reimbursement negotiations, especially outside the US, remain critical unknowns.
In the UK, the National Institute for Health and Care Excellence (NICE) is currently evaluating Leqembi for potential use on the NHS. The subcutaneous version may influence NICE’s assessment, as reduced administration costs could improve the drug’s cost-effectiveness. The Alzheimer’s Society has welcomed the development, emphasising that any treatment that simplifies care could ease pressure on NHS memory clinics.
The broader Alzheimer’s drug market is increasingly competitive, with Eli Lilly’s donanemab also seeking approvals globally. For UK pension funds with exposure to healthcare equities, the Leqembi approval reinforces the sector’s growth narrative, but investors should remain aware of regulatory and pricing risks that could affect long-term returns.